STING protein is a mediator of innate immunity and a candidate for auto immune disease or cancer immunotherapy. Clinical trials are already ongoing, and targeting all STING variants has become crucial. R232 is the most common variant, and HAQ and H232 alleles are also present in the human population.
To help progress your research in identifying and charaterizing potential universal new STING therapeutics, Revvity has developed this note with:
For research use only. Not for use in diagnostic procedures.
Unlock your STING polymorphism research with a comprehensive HTRF binding platform